Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.100
+0.020 (1.85%)
At close: May 13, 2025, 4:00 PM
1.100
0.00 (0.00%)
Pre-market: May 14, 2025, 5:34 AM EDT
Femasys Employees
As of December 31, 2024, Femasys had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees increased by 37 or 108.82% compared to the previous year.
Employees
71
Change (1Y)
37
Growth (1Y)
108.82%
Revenue / Employee
$23,933
Profits / Employee
-$297,380
Market Cap
29.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
FEMY News
- 5 days ago - Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations - GlobeNewsWire
- 2 months ago - Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewsWire
- 2 months ago - Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach - GlobeNewsWire
- 2 months ago - Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials - GlobeNewsWire
- 3 months ago - Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices - GlobeNewsWire
- 3 months ago - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control - GlobeNewsWire